List of Bonjesta drug patents

Bonjesta is owned by Duchesnay.

Bonjesta contains Doxylamine Succinate; Pyridoxine Hydrochloride.

Bonjesta has a total of 4 drug patents out of which 0 drug patents have expired.

Bonjesta was authorised for market use on 07 November, 2016.

Bonjesta is available in tablet, extended release;oral dosage forms.

Bonjesta can be used as treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management.

The generics of Bonjesta are possible to be released after 18 February, 2033.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9937132 DUCHESNAY Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
Feb, 2033

(10 years from now)

US9375404 DUCHESNAY Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
Feb, 2033

(10 years from now)

US9526703 DUCHESNAY Plurimodal release formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
Feb, 2033

(10 years from now)

US9089489 DUCHESNAY Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
Feb, 2033

(10 years from now)

Drugs and Companies using DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE ingredient

Market Authorisation Date: 07 November, 2016

Treatment: Treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of BONJESTA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic